Identification
- Summary
Iodide I-123 is a radiopharmaceutical diagnostic agent used for the evaluation of the thyroid function and/or morphology.
- Generic Name
- Iodide I-123
- DrugBank Accession Number
- DB09420
- Background
Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123.
Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Iodide I-123 (DB09420)
- Weight
- Average: 122.9061
Monoisotopic: 122.906146524 - Chemical Formula
- I
- Synonyms
- 123I−
- I 123
- I-123
- Iodide ion i-123
- Iodine 123
- Iodine-123
Pharmacology
- Indication
Administration of Sodium Iodide I 123 Capsules is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Sodium Iodide I-123 is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4).
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Iodine-123 decays by electron capture with a physical half-life of 13.2 hours
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Limit iodine intake. Consume a low iodine diet for two weeks before the administration of Iodide I-123.
- Take on an empty stomach. Fasting before the use of I-123 for imaging of the thyroid may increase accuracy.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sodium iodide I-123 29UKX3A616 41927-88-2 FVAUCKIRQBBSSJ-VVUPZWBASA-M - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image I 123 Mini Capsule 10 mCi/1 Oral Anazao Health Corporation 2012-05-23 Not applicable US 
Sodium Iodide Capsule 200 uCi/1 Oral Amersham Health Inc. 2006-07-10 Not applicable US Sodium Iodide Capsule 100 uCi/1 Oral Amersham Health Inc. 2006-07-10 Not applicable US Sodium Iodide I 123 Capsule, gelatin coated 100 uCi/1 Oral Cardinal Health 418, Inc 2003-01-02 Not applicable US Sodium Iodide I 123 Capsule, gelatin coated 400 uCi/1 Oral Cardinal Health 418, Inc 2003-01-02 2013-09-30 US Sodium Iodide I 123 Capsule, gelatin coated 200 uCi/1 Oral Cardinal Health 418, Inc 2003-01-02 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Sodium Iodide I 123 Capsule, gelatin coated 200 uCi/1 Oral Mallinckrodt 2007-04-11 2017-07-01 US Sodium Iodide I 123 Capsule, gelatin coated 200 uCi/1 Oral Curium US LLC 2007-04-11 Not applicable US Sodium Iodide I 123 Capsule, gelatin coated 100 uCi/1 Oral Mallinckrodt 2007-04-11 2017-07-01 US Sodium Iodide I 123 Capsule, gelatin coated 100 uCi/1 Oral Curium US LLC 2015-11-04 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image I 123 Mini Iodide I-123 (10 mCi/1) Capsule Oral Anazao Health Corporation 2012-05-23 Not applicable US
Categories
- ATC Codes
- V09FX02 — Sodium iodide (123i)
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as homogeneous halogens. These are inorganic non-metallic compounds in which the largest atom is a nobel gas.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous non-metal compounds
- Class
- Homogeneous halogens
- Sub Class
- Not Available
- Direct Parent
- Homogeneous halogens
- Alternative Parents
- Not Available
- Substituents
- Homogeneous halogen
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 98QPV8670C
- CAS number
- 69239-56-1
- InChI Key
- XMBWDFGMSWQBCA-AHCXROLUSA-M
- InChI
- InChI=1S/HI/h1H/p-1/i1-4
- IUPAC Name
- (123I)iodide
- SMILES
- [123I-]
References
- General References
- Not Available
- External Links
- PubChem Compound
- 135300
- PubChem Substance
- 347827850
- ChemSpider
- 119193
- 1361657
- ChEMBL
- CHEMBL1249
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Iodine-123
- FDA label
- Download (2.79 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Enrolling by Invitation Diagnostic Dementia / Mild Cognitive Impairment (MCI) / Parkinsonism / Rapid Eye Movement Sleep Behavior Disorder 1 2 Completed Diagnostic Melancholic Depression 1 2, 3 Recruiting Diagnostic Malignancy of Thyroid Nodules 1 1 Terminated Diagnostic Alzheimer's Disease (AD) 1 Not Available Completed Not Available Congestive Heart Failure (CHF) 1 Not Available Completed Not Available Parkinson's Disease (PD) 1 Not Available Completed Diagnostic Heart Failure 1 Not Available Completed Diagnostic Stress Induced Cardiomyopathy 1 Not Available Withdrawn Not Available Thyroid Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral 10 mCi/1 Capsule Oral Injection, solution Intravenous Capsule Oral 100 uCi/1 Capsule Oral 200 uCi/1 Capsule, gelatin coated Oral 100 uCi/1 Capsule, gelatin coated Oral 200 uCi/1 Capsule, gelatin coated Oral 400 uCi/1 - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 1.02 Chemaxon pKa (Strongest Acidic) -9 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 13.95 m3·mol-1 Chemaxon Polarizability 5.07 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at November 30, 2015 19:10 / Updated at June 12, 2020 16:52